Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety
- Conditions
- Generalised Anxiety Disorder
- Interventions
- Behavioral: Cognitive Behavioural Therapy
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- University College, London
- Target Recruit Count
- 5
- Registration Number
- NCT02347033
- Locations
- 🇬🇧
Camden & Islington (with Kingston), London, United Kingdom
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
- Conditions
- Acute Kidney InjuryDepression
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 3255526
- Registration Number
- NCT02320240
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Existing depression medication treatment
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 10
- Registration Number
- NCT02269540
- Locations
- 🇨🇦
Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Integral Assessment in Unipolar Depression
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 100
- Registration Number
- NCT02268487
- Locations
- 🇧🇷
Insitute of Psychiatry of the University of São Paulo, São Paulo, Brazil
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
- Conditions
- Major Depression
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT02237937
- Locations
- 🇩🇪
Max Planck Institute of Psychiatry, Munich, Bavaria, Germany
Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- The Cooper Health System
- Target Recruit Count
- 2
- Registration Number
- NCT02235064
- Locations
- 🇺🇸
Cooper University Hospital, Camden, New Jersey, United States
Observational Study to Assess a 6-months Treatment With Gladem
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 546
- Registration Number
- NCT02231268
The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 25
- Registration Number
- NCT02228005
- Locations
- 🇨🇦
Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada
Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep
- Conditions
- Generalized Anxiety DisorderSocial PhobiaSeparation Anxiety Disorder
- Interventions
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 14
- Registration Number
- NCT02189213
- Locations
- 🇺🇸
NYSPI, New York, New York, United States
Effects and Consequences for Mother and Child From Treatment for Depression
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Katarina Wide
- Target Recruit Count
- 17
- Registration Number
- NCT02185547
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.